A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525113-22-00

Enrollment

Registered

2026-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: May 30, 2026